Association of American Cancer Institutes

Cancer Drug Parity Act Gains Strong Support from Leading Healthcare Organizations

Retrieved on: 
Wednesday, November 8, 2023
EBP, Insurance, Attention, ONS, Act, AIM, Public policy, International Myeloma Foundation, IV, Congress, House, Legislation, Face, IMF, RN, Multiple myeloma, CLL, AIM at Melanoma Foundation, Disease, Melanoma, DNP, ACS, Representative, Parity, Oncology Nursing Society, Association of American Cancer Institutes, Cancer, American Cancer Society Cancer Action Network, Oral cancer, Patient, ASCO, Lymphoma, Health insurance, Pharmaceutical industry, Nursing, Dietary supplement

The International Myeloma Foundation (IMF), which leads the Coalition to Improve Access to Cancer Care (CIACC), fervently supports the Cancer Drug Parity Act, recognizing its profound impact on myeloma patients and their families.

Key Points: 
  • The International Myeloma Foundation (IMF), which leads the Coalition to Improve Access to Cancer Care (CIACC), fervently supports the Cancer Drug Parity Act, recognizing its profound impact on myeloma patients and their families.
  • The Cancer Drug Parity Act would put the needs of patients first to ensure that patients, along with their healthcare providers, can choose the treatment option they deem is most appropriate”.
  • ONS is proud to support the Cancer Drug Parity Act and commends the bill’s sponsors for their leadership in ensuring parity for oral cancer treatments.”
    Recognizing the pressing need for equitable access to cancer treatments, Lisa Lacasse, president of the American Cancer Society Cancer Action Network (ACS CAN), emphasized the critical issue of disparities in cost-sharing for oral chemotherapy medications.
  • For more information on the Cancer Drug Parity Act and its potential impact on cancer care, please visit https://www.access2cancercare.org/ .

Research to Be Presented at ISPOR 2023 Illuminates the Economic Costs of Melanoma and Non-Small Cell Lung Cancer and Provides Insights That Can Help Strengthen the Quality and Approach to Real-World Evidence Generation

Retrieved on: 
Friday, May 5, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Partnership, Drug development, Professional, ISPOR, McKesson Corporation, Cancer, MBA, RWD, Lung cancer, Electronic health record, Doctor of Philosophy, CDS, Association of American Cancer Institutes, MD, EHR, Patient, Melanoma, RWE, Metastasis, Continuum, Disease, Medical imaging, Nursing, Medical device, NSCLC

“It’s an unprecedented time for patients living with cancer as life sciences companies race to create and expand access to new cutting-edge targeted therapies.

Key Points: 
  • “It’s an unprecedented time for patients living with cancer as life sciences companies race to create and expand access to new cutting-edge targeted therapies.
  • With this level of innovation comes increased complexity and cost for manufacturers, providers, and patients,” said Susan Shiff, PhD, MBA, president, Ontada.
  • “Ontada’s work continues to support science in oncology and improve cancer care through our real-world data and research.
  • The study concludes that CDS tools can have a significant impact on assisting providers in identifying precision oncology treatment options.

Dr. Susan Love Foundation for Breast Cancer Research Hosts 3rd Annual Love is in the Air

Retrieved on: 
Thursday, February 16, 2023
Government, True Patriot Love Foundation, Atmosphere of Earth, Love, Season, Laureus Lifetime Achievement Award, Partners for Community Impact, Breast cancer, Association of American Cancer Institutes, Oncology, Breast Cancer Research Foundation, Breast Cancer Research, LOVE, Memorial Sloan Kettering Cancer Center, Person, PACI, Research, BCRF, Breast, Cancer, MD, Birth control

LOS ANGELES, Feb. 16, 2023 /PRNewswire/ -- Dr. Susan Love Foundation for Breast Cancer Research is delighted to announce the 3rd Annual Love is in the Air Luncheon celebration.

Key Points: 
  • LOS ANGELES, Feb. 16, 2023 /PRNewswire/ -- Dr. Susan Love Foundation for Breast Cancer Research is delighted to announce the 3rd Annual Love is in the Air Luncheon celebration.
  • The annual Love is in the Air luncheon brings together persons affected by breast cancer, their supporters and champions dedicated to a world without breast cancer.
  • As the Founding Scientific Director of the Breast Cancer Research Foundation, Dr. Norton is involved in collaborations with BCRF investigators on projects aimed at improving treatments in breast cancer, and advancing understanding of metastatic breast cancer.
  • The Foundation invites all to attend and celebrate LOVE and honor those dedicated to ending breast cancer.

Mediaplanet Partners with Chuck D and Oncology Experts in Campaign to Shed Light on Cancer Care Innovations

Retrieved on: 
Saturday, September 25, 2021
Association of American Cancer Institutes, Social media, QIAGEN, Clinical trial, ACS, Food, Interview, Congress, Society, Sophia, USA, USA TODAY, Speedy Trial Act, Patient, Community Movement, Association, Blood, Epic Sciences, Fred Hutchinson Cancer Research Center, American Cancer Society Cancer Action Network, American Society of Clinical Oncology, Travel, Death, Legislation, Awareness, Risk, Baylor St. Luke's Medical Center, Technology, American Society for Clinical Pathology, GENETICS, Health equity, Colorectal cancer, Color, Medical Center, Time, Pharmaceutical industry

NEW YORK, Sept. 25, 2021 /PRNewswire-PRWeb/ -- Mediaplanet announces the launch of its print and digital campaign entitled "Transforming Cancer Care."

Key Points: 
  • NEW YORK, Sept. 25, 2021 /PRNewswire-PRWeb/ -- Mediaplanet announces the launch of its print and digital campaign entitled "Transforming Cancer Care."
  • Cancer care disparities are vast when it comes to socio-economic status and race.
  • This oftentimes means that people in some racial groups do not have the same level of access to the latest advancements and best care in cancer.
  • "One of the most common barriers to trial participation is location," says Lisa A. Lacasse, president of the American Cancer Society Cancer Action Network (ACS CAN).

NCCN Announces UC Davis Comprehensive Cancer Center as 31st Member Institution

Retrieved on: 
Tuesday, March 23, 2021
Cancer organizations, Cancer research, UC Davis Comprehensive Cancer Center, National Comprehensive Cancer Network, NCCN, Cancer, National Cancer Institute, Association of American Cancer Institutes

PLYMOUTH MEETING, Pa., March 23, 2021 /PRNewswire/ -- The National Comprehensive Cancer Network ( NCCN ) today announced that its Board of Directors has voted to elect University of California (UC) Davis Comprehensive Cancer Center as its newest Member Institution.

Key Points: 
  • PLYMOUTH MEETING, Pa., March 23, 2021 /PRNewswire/ -- The National Comprehensive Cancer Network ( NCCN ) today announced that its Board of Directors has voted to elect University of California (UC) Davis Comprehensive Cancer Center as its newest Member Institution.
  • "UC Davis leverages strengths in innovative cancer care models and technologies, precision therapeutics, transformative imaging, and mitigation of cancer risks and disparities to reduce the cancer burden in their region and beyond.
  • UC Davis Comprehensive Cancer Center is the only National Cancer Institute-designated center serving the Central Valley and inland Northern California, a region of more than 6 million people.
  • "We are extremely pleased to become a member of NCCN, collaborating with many of the nation's leading cancer centers in enhancing and facilitating exceptional cancer care," said Primo "Lucky" Lara, Jr., MD, Director, UC Davis Comprehensive Cancer Center.

Memorial Cancer Institute Together with Florida Atlantic University Research Partnership Earns 'Florida Cancer Center of Excellence' Designation

Retrieved on: 
Thursday, March 4, 2021
University of Florida, NCI-designated Cancer Center, Health care, Hospitals, H. Lee Moffitt Cancer Center & Research Institute, Medicine, H. Lee Moffitt, Moffitt, Association of American Cancer Institutes, National Comprehensive Cancer Network

The alliance between Memorial's Cancer Institute and FAU (MCIFAU) has been recognized by the state's Department of Health as a "Florida Cancer Center of Excellence."

Key Points: 
  • The alliance between Memorial's Cancer Institute and FAU (MCIFAU) has been recognized by the state's Department of Health as a "Florida Cancer Center of Excellence."
  • Memorial Cancer Institute is one of the largest cancer centers in Florida, treating more than 4,300 new cancer patients a year.
  • MCIFAU joins the University of Florida Health Cancer Center, H. Lee Moffitt Cancer Center and Research Institute, Mayo Clinic Florida, and the University of Miami Sylvester Comprehensive Cancer Center as Florida Cancer Centers of Excellence.
  • Florida Atlantic University, established in 1961, officially opened its doors in 1964 as the fifth public university in Florida.

Break Through Cancer Launches Collaborative Model Across Top U.S. Research Institutions in Pursuit of Cancer Cures

Retrieved on: 
Thursday, February 25, 2021
Research, Philanthropy, Other Health, Health, General Health, Other Philanthropy, Other Science, Science, Oncology, Cancer organizations, NCI-designated Cancer Center, National Comprehensive Cancer Network, Sidney Kimmel Comprehensive Cancer Center, Cancer research, MD Anderson Cancer Center, Dana–Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Association of American Cancer Institutes

Multidisciplinary research teams will be selected from across five participating institutions: Dana-Farber Cancer Institute, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, and the Koch Institute for Integrative Cancer Research at MIT.

Key Points: 
  • Multidisciplinary research teams will be selected from across five participating institutions: Dana-Farber Cancer Institute, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, and the Koch Institute for Integrative Cancer Research at MIT.
  • Break Through Cancers model builds on the outstanding efforts of the broader cancer research community and presents the potential for major advances in our shared fight against these intractable cancers, said Dr. Jacks, President of Break Through Cancer.
  • Break Through Cancer ( www.breakthroughcancer.org ) is a public foundation that brings several of the top cancer research centers together to collaborate on and accelerate research, clinical trials, and ultimately cures for the deadliest cancers.
  • Break Through Cancer is currently partnering with Dana-Farber Cancer Institute, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, and the Koch Institute for Integrative Cancer Research at MIT.

Seattle Cancer Care Alliance Among First Washington Healthcare Providers to Receive COVID-19 Vaccine

Retrieved on: 
Tuesday, December 15, 2020
Oncology, Health, Infectious diseases, Hospitals, Practice Management, Pharmaceutical, Biotechnology, Seattle Cancer Care Alliance, National Comprehensive Cancer Network, Fred Hutchinson Cancer Research Center, Health care, Healthcare in the United States, Medicine, Association of American Cancer Institutes, Nancy E. Davidson

Seattle Cancer Care Alliance (SCCA), the only National Comprehensive Cancer Network (NCCN)- member cancer center in Washington state, was selected by the Washington State Department of Health to be one of the first 17 sites to receive the recently authorized COVID-19 vaccine.

Key Points: 
  • Seattle Cancer Care Alliance (SCCA), the only National Comprehensive Cancer Network (NCCN)- member cancer center in Washington state, was selected by the Washington State Department of Health to be one of the first 17 sites to receive the recently authorized COVID-19 vaccine.
  • View the full release here: https://www.businesswire.com/news/home/20201215006171/en/
    Michelle Vincent, Pharmacy Tech Lead, with the first doses of the COVID-19 vaccine delivered to Seattle Cancer Care Alliance.
  • Seattle Cancer Care Alliance (SCCA) brings together the leading research teams and cancer specialists from Fred Hutch, Seattle Childrens and UW Medicine one extraordinary group whose sole purpose is the pursuit of better, longer, richer lives for our patients.
  • Based in Seattles South Lake Union neighborhood, SCCA is the only National Cancer Institute (NCI)-designated cancer center in Washington state, as part of the University of Washington Medicine, Fred Hutchinson Cancer Research Center and Seattle Childrens consortium.

JNCCN: Improving COVID-19 Safety for Cancer Patients and Healthcare Providers

Retrieved on: 
Thursday, April 9, 2020
Health, National Comprehensive Cancer Network, Hospitals, NCI-designated Cancer Center, Yale Cancer Center, H. Lee Moffitt Cancer Center & Research Institute, Seattle Cancer Care Alliance, The James Cancer Hospital, Association of American Cancer Institutes, Gibbs Cancer Center & Research Institute

The nonprofit organization's Best Practices Committee has published a new article online-ahead-of-print in JNCCNJournal of the National Comprehensive Cancer Network detailing their recommendations for keeping cancer patients, caregivers and staff as safe as possible.

Key Points: 
  • The nonprofit organization's Best Practices Committee has published a new article online-ahead-of-print in JNCCNJournal of the National Comprehensive Cancer Network detailing their recommendations for keeping cancer patients, caregivers and staff as safe as possible.
  • "We are doing everything we can to review and share reliable information that will help keep oncology patients, providers, and staff safe under the new reality of increased risk."
  • "People with cancer and their loved ones already go through so much, and now they face new fears around catching COVID-19 or delaying necessary treatment.
  • In addition to Dr. Cinar, the article includes authors from Abramson Cancer Center at the University of Pennsylvania, Duke Cancer Institute, Fred & Pamela Buffett Cancer Center, Mayo Clinic Cancer Center, Moffitt Cancer Center, Ohio State Comprehensive Cancer Center James Cancer Hospital and Solove Research Institute, Seattle Cancer Care Alliance (including Fred Hutchinson Research Center and University of Washington), University of Colorado Cancer Center, and Yale Cancer Center/Smilow Cancer Hospital.

JNCCN: Improving COVID-19 Safety for Cancer Patients and Healthcare Providers

Retrieved on: 
Thursday, April 9, 2020
Health, National Comprehensive Cancer Network, NCI-designated Cancer Center, Yale Cancer Center, The James Cancer Hospital, H. Lee Moffitt Cancer Center & Research Institute, Seattle Cancer Care Alliance, Duke Cancer Institute, Association of American Cancer Institutes, UCSF Helen Diller Family Comprehensive Cancer Center

Visit NCCN.org/covid-19 for continually-updated resources for patients, providers, and care systems.

Key Points: 
  • Visit NCCN.org/covid-19 for continually-updated resources for patients, providers, and care systems.
  • PLYMOUTH MEETING, Pennsylvania, April 9, 2020 /PRNewswire/ -- The National Comprehensive Cancer Network ( NCCN )an alliance of leading cancer centers is continuing to share new resources for optimal cancer management amid new and changing challenges related to the Coronavirus Disease 2019 ( COVID-19 ).
  • The nonprofit organization's Best Practices Committee has published a new article online-ahead-of-print in JNCCNJournal of the National Comprehensive Cancer Network detailing their recommendations for keeping cancer patients, caregivers and staff as safe as possible.
  • In addition to Dr. Cinar, the article includes authors from Abramson Cancer Center at the University of Pennsylvania, Duke Cancer Institute, Fred & Pamela Buffett Cancer Center, Mayo Clinic Cancer Center, Moffitt Cancer Center, Ohio State Comprehensive Cancer Center James Cancer Hospital and Solove Research Institute, Seattle Cancer Care Alliance (including Fred Hutchinson Research Center and University of Washington), University of Colorado Cancer Center, and Yale Cancer Center/Smilow Cancer Hospital.